Last reviewed · How we verify
GC1107
GC1107 is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from inhibiting T cell activation.
GC1107 is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from inhibiting T cell activation. Used for Non-small cell lung cancer, Other solid tumors (under investigation).
At a glance
| Generic name | GC1107 |
|---|---|
| Sponsor | Green Cross Corporation |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GC1107 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 receptors on T cells. This blockade restores T cell proliferation, activation, and anti-tumor cytotoxic function. The mechanism is similar to other PD-L1 inhibitors used in immuno-oncology.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation)
Common side effects
- Fatigue
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
Key clinical trials
- To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults (PHASE3)
- To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC1107 CI brief — competitive landscape report
- GC1107 updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI